SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy gets US nod to sell Alzheimer's generic

22 Sep 2010 Evaluate

Ranbaxy may get the final FDA approval to market the drug known under the brand name, Aricept, as soon as patent protection over the drug expires on November 25.Aricept raked in sales of about $3.2 billion globally last fiscal, 60% of which came from the US, the world’s largest pharmaceutical market. 

 

The exclusivity status was confirmed by the US regulator, the Food and Drug Administration (FDA), after it dismissed Israeli drug major Teva’s claim for a shared marketing exclusivity for the drug. The drug will fetch Ranbaxy about $300 million (Rs 1,370 crore) during the exclusivity period.

crackcrack
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×